How Useful Are Early Economic Models? Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling"

被引:16
作者
Love-Koh, James [1 ]
机构
[1] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
关键词
Early Model; Cost-Effectiveness Analysis; Economic Evaluation; Decision Modelling; PRODUCT DEVELOPMENT; MEDICAL DEVICES; HEADROOM; NICE; CARE;
D O I
10.15171/ijhpm.2019.119
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Early economic modelling has long been recommended to aid research and development (R&D) decisions in medical innovation, although they are less frequently published and critically appraised. A review of 30 innovations by Grutters et al provides an opportunity to evaluate how early models are used in practice. The evidence of early models can be used to inform two types of decision: to continue development ("stop or go") or to alter future R&D activities. I argue that early models have limited use in stop or go decisions, as less resource and data undermine the reliability of the models' indicative estimates of cost-effectiveness. Whilst they are far more useful for informing future R&D directions, the best techniques available from statistical decision science, such as value of information analysis, are not regularly used. It is highly recommended that early models adopt these methods to best deal with uncertainty, quantify the potential value of further research, identify areas of study with the greatest potential benefit and generate recommendations on study design and sample size.
引用
收藏
页码:215 / 217
页数:3
相关论文
共 19 条
  • [1] Early Economic Evaluation of Diagnostic Technologies: Experiences of the NIHR Diagnostic Evidence Co-operatives
    Abel, Lucy
    Shinkins, Bethany
    Smith, Alison
    Sutton, Andrew J.
    Sagoo, Gurdeep S.
    Uchegbu, Ijeoma
    Allen, A. Joy
    Graziadio, Sara
    Moloney, Eoin
    Yang, Yaling
    Hall, Peter
    [J]. MEDICAL DECISION MAKING, 2019, 39 (07) : 857 - 866
  • [2] Estimating the cost of new drug development: Is it really $802 million?
    Adams, CP
    Brantner, VV
    [J]. HEALTH AFFAIRS, 2006, 25 (02) : 420 - 428
  • [3] Annemans L, 2000, Value Health, V3, P427, DOI 10.1046/j.1524-4733.2000.36007.x
  • [4] Modelling in health economic evaluation - What is its place? What is its value?
    Brennan, A
    Akehurst, R
    [J]. PHARMACOECONOMICS, 2000, 17 (05) : 445 - 459
  • [5] Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra
    Claxton, K
    Sculpher, M
    McCabe, C
    Briggs, A
    Akehurst, R
    Buxton, M
    Brazier, J
    O'Hagan, T
    [J]. HEALTH ECONOMICS, 2005, 14 (04) : 339 - 347
  • [6] Nasty or Nice? A Perspective on the Use of Health Technology Assessment in the United Kingdom
    Drummond, Michael
    Sorenson, Corinna
    [J]. VALUE IN HEALTH, 2009, 12 : S8 - S13
  • [7] A Novel Method to Value Real Options in Health Care: The Case of a Multicohort Human Papillomavirus Vaccination Strategy
    Favato, Giampiero
    Baio, Gianluca
    Capone, Alessandro
    Marcellusi, Andrea
    Mennini, Francesco Saverio
    [J]. CLINICAL THERAPEUTICS, 2013, 35 (07) : 904 - 914
  • [8] HEADROOM APPROACH TO DEVICE DEVELOPMENT: CURRENT AND FUTURE DIRECTIONS
    Girling, Alan
    Lilford, Richard
    Cole, Amanda
    Young, Terry
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2015, 31 (05) : 331 - 338
  • [9] Grutters JPC, 2019, INT J HEALTH POLICY, V8, P575, DOI [10.15171/ijhpm.2019.36, 10.15171/IJHPM.2019.36]
  • [10] Early assessment of medical technologies to inform product development and market access: A review of methods and applications
    Ijzerman M.J.
    Steuten L.M.G.
    [J]. Applied Health Economics and Health Policy, 2011, 9 (5) : 331 - 347